Ars Pharmaceuticals Inc (SPRY)

$SPRY $AXSM $ASTS $GSAT $RKLB (NASDAQ) — This isn’t a donation or a casino bet… it’s a once-in-a-lifetime setup 🧨 (currently $8/share Roth initiated Price Target $40) Only globally approved, needle-free EpiPen epinephrine alternative → protected through 2039 Millions face life-threatening anaphylaxis daily → this replaces the needle ~22M+ shares short / ~45–48% of float → extreme positioning + fuel 20+ days to cover → pressure builds if demand accelerates $72.2M year-one U.S. revenue → demand is real 22,500+ prescribers, ~50% repeat → refill engine starting 2026 = shift to renewals → compounding revenue begins $84.3M FY revenue + $28.1M Q4 → acceleration underway Global rollout: EU, China, Australia → Canada next ~90% real-world success (single dose) → clinically validated 9,000+ schools onboarded → embedded distribution channel $0 copay + expanding coverage → unlocking mass adoption DTC + direct access → removing friction, scaling fast Sales force expanding → deeper penetration in 2026 $245M cash → runway to breakeven Urticaria pipeline → platform upside ALK partnership → global scale leverage Full details: https://www.globenewswire.com/news-release/2026/03/09/3251623/0/en/ARS-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Updates-on-neffy-epinephrine-nasal-spray-Commercialization.html Learn more about neffy: http://neffy.com/about/ Global partner (ALK): http://alk.net/our-solutions Bottom line: De-risked, commercial-stage biotech with scaling adoption, global tailwinds, and a compounding revenue model 🔥

$MIST At most an $8 stock. $SPRY is a one trick pony as well. A merger would be ideal. Have been holding a year now. I expect ER will provide a much needed boost.

$SPRY I just got in, saw the ad, know numerous people that deal with this. let's take a ride and see where it goes.

$CADL $SPRY bull case: Needle-free neffy hammer 2025 w/ $72M US rev, $245M cash to breakeven. Catalysts: Japan launch Q1’26 (Alfresa), Canada approval/launch Q2’26 (ALK), urticaria Ph2b data mid’26 (TAM doubler to $2B+ US). 98% global moat—approvals: US (FDA 2mg/1mg), EU (EURneffy 2mg/1mg w/ CHMP Jan’26), China (NMPA Dec’25 via Pediatrix), Australia (TGA Dec’25 2mg/1mg via CSL Seqirus), New Zealand (via CSL Seqirus partnership). Wartime/econ resilient: Essential med demand surges in conflicts/downturns like #IranWar tensions or #WarEconomy slumps. Comps re-rate 300%+; 48% short float = squeeze potential. DCF $16-25+! 🚀 #Biotech #SPRY #Investing #EconomicDownturn #GeopoliticalRisk #iran #war #worldwar #navy #army #marines

$RDDT $SPRY bull case: Needle-free neffy pounds 2025 w/ $72M US rev, $245M cash to breakeven. Catalysts: Japan launch Q1’26 (Alfresa), Canada approval/launch Q2’26 (ALK), urticaria Ph2b data mid’26 (TAM doubler to $2B+ US). 98% global moat—approvals: US (FDA 2mg/1mg), EU (EURneffy 2mg/1mg w/ CHMP Jan’26), China (NMPA Dec’25 via Pediatrix), Australia (TGA Dec’25 2mg/1mg via CSL Seqirus), New Zealand (via CSL Seqirus partnership). Wartime/econ resilient: Essential med demand surges in conflicts/downturns like #IranWar tensions or #WarEconomy slumps. Comps re-rate 300%+; 48% short float = squeeze potential. DCF $16-25+! 🚀 #Biotech #SPRY #Investing #EconomicDownturn #GeopoliticalRisk #iran #war #worldwar #navy #army #marines

$RKLB $SPRY bull case: Needle-free neffy (only new epi pen alternative) smashes 2025 w/ $72M US rev, $245M cash to breakeven. Catalysts: Japan launch Q1’26 (Alfresa), Canada approval/launch Q2’26 (ALK), urticaria Ph2b data mid’26 (TAM doubler to $2B+ US). 98% global moat—approvals: US (FDA 2mg/1mg), EU (EURneffy 2mg/1mg w/ CHMP Jan’26), China (NMPA Dec’25 via Pediatrix), Australia (TGA Dec’25 2mg/1mg via CSL Seqirus), New Zealand (via CSL Seqirus partnership). Wartime/econ resilient: Essential med demand surges in conflicts/downturns like #IranWar tensions or #WarEconomy slumps. Comps re-rate 300%+; 48% short float = squeeze potential. DCF $16-25+! 🚀 #Biotech #SPRY #Investing #EconomicDownturn #GeopoliticalRisk #iran #war #worldwar #navy #army #marines

$NVDA $SPRY bull case: Needle-free neffy makes hay 2025 w/ $72M US rev, $245M cash to breakeven. Catalysts: Japan launch Q1’26 (Alfresa), Canada approval/launch Q2’26 (ALK), urticaria Ph2b data mid’26 (TAM doubler to $2B+ US). 98% global moat—approvals: US (FDA 2mg/1mg), EU (EURneffy 2mg/1mg w/ CHMP Jan’26), China (NMPA Dec’25 via Pediatrix), Australia (TGA Dec’25 2mg/1mg via CSL Seqirus), New Zealand (via CSL Seqirus partnership). Wartime/econ resilient: Essential med demand surges in conflicts/downturns like #IranWar tensions or #WarEconomy slumps. Comps re-rate 300%+; 48% short float = squeeze potential. DCF $16-25+! 🚀 #Biotech #SPRY #Investing #EconomicDownturn #GeopoliticalRisk #iran #war #worldwar #navy #army #marines

$UBER $SPRY bull case: Needle-free neffy hammers 2025 w/ $72M US rev, $245M cash to breakeven. Catalysts: Japan launch Q1’26 (Alfresa), Canada approval/launch Q2’26 (ALK), urticaria Ph2b data mid’26 (TAM doubler to $2B+ US). 98% global moat—approvals: US (FDA 2mg/1mg), EU (EURneffy 2mg/1mg w/ CHMP Jan’26), China (NMPA Dec’25 via Pediatrix), Australia (TGA Dec’25 2mg/1mg via CSL Seqirus), New Zealand (via CSL Seqirus partnership). Wartime/econ resilient: Essential med demand surges in conflicts/downturns like #IranWar tensions or #WarEconomy slumps. Comps re-rate 300%+; 48% short float = squeeze potential. DCF $16-25+! 🚀 #Biotech #SPRY #Investing #EconomicDownturn #GeopoliticalRisk #iran #war #worldwar #navy #army #marines

$OKLO $SPRY bull case: Needle-free neffy kills 2025 w/ $72M US rev, $245M cash to breakeven. Catalysts: Japan launch Q1’26 (Alfresa), Canada approval/launch Q2’26 (ALK), urticaria Ph2b data mid’26 (TAM doubler to $2B+ US). 98% global moat—approvals: US (FDA 2mg/1mg), EU (EURneffy 2mg/1mg w/ CHMP Jan’26), China (NMPA Dec’25 via Pediatrix), Australia (TGA Dec’25 2mg/1mg via CSL Seqirus), New Zealand (via CSL Seqirus partnership). Wartime/econ resilient: Essential med demand surges in conflicts/downturns like #IranWar tensions or #WarEconomy slumps. Comps re-rate 300%+; 48% short float = squeeze potential. DCF $16-25+! 🚀 #Biotech #SPRY #Investing #EconomicDownturn #GeopoliticalRisk #iran #war #worldwar #navy #army #marines